Immatics N.V. Ordinary Shares
IMTXImmatics N.V. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company specializes in T-cell receptor (TCR) therapies, aiming to harness the immune system to target and destroy tumor cells. Based in Germany, Immatics advances personalized medicine approaches through its proprietary technological platform to identify and develop targeted treatments for various cancers.
Company News
Immatics reported promising initial anti-tumor activity for its second-generation PRAME cell therapy IMA203CD8 in a Phase 1a dose escalation trial, showing encouraging clinical responses across multiple cancer types, particularly in ovarian carcinoma.
Immatics N.V. plans to sell 12.5 million ordinary shares at $10.00 per share, expecting to raise $125 million in a public offering managed by Jefferies, Leerink Partners, and Cantor.
Immatics reported promising Phase 1a clinical trial results for two bispecific cancer therapies, IMA402 and IMA401, demonstrating favorable tolerability and deep, durable responses in heavily pre-treated patients with solid tumors across multiple cancer types.
Immatics N.V. announced the appointment of Venkat Ramanan, Ph.D. as its new Chief Financial Officer, replacing Arnd Christ. Dr. Ramanan brings over 25 years of biopharmaceutical finance experience from companies like Seagen, Gilead Sciences, and Amgen.
The T-cell receptor (TCR) therapy pipeline is rapidly expanding, with over 80 pharmaceutical companies actively developing more than 100 TCR therapies for various cancers, including solid tumors. Several promising pipeline candidates are in different stages of clinical trials, showcasing the potential of TCR therapy to revolutionize cancer treatm...
